• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: which cutoff should be used?

作者信息

Lein M, Stephan C, Jung K, Schnorr D, Loening S

机构信息

Department of Urology, University Hospital Charité, Humboldt University, Berlin, Germany.

出版信息

Cancer Invest. 1998;16(1):45-9. doi: 10.3109/07357909809039753.

DOI:10.3109/07357909809039753
PMID:9474251
Abstract

A review on literature data is given concerning free prostate-specific antigen (f-PSA) and the corresponding cutoffs of f-PSA/t-PSA for differentiating patients with cancer of the prostate from those with benign prostatic hyperplasia. The special importance of the diagnostic criterion (sensitivity, specificity, efficiency) for establishing the cutoff is demonstrated. On the basis of our own data, the application of the f-PSA% is recommended as an additional decision criterion for biopsy.

摘要

相似文献

1
Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: which cutoff should be used?
Cancer Invest. 1998;16(1):45-9. doi: 10.3109/07357909809039753.
2
[Prostate-specific antigen as a tumor marker of prostate carcinoma].[前列腺特异性抗原作为前列腺癌的肿瘤标志物]
Ned Tijdschr Geneeskd. 1999 Aug 21;143(34):1733-8.
3
On the clinical usefulness of the free-to-total prostate-specific antigen ratio.
Int J Biol Markers. 2006 Jan-Mar;21(1):1-5. doi: 10.5301/jbm.2008.3846.
4
Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.利用游离前列腺特异性抗原百分比增强前列腺癌与良性前列腺疾病的鉴别诊断：一项前瞻性多中心临床试验
JAMA. 1998 May 20;279(19):1542-7. doi: 10.1001/jama.279.19.1542.
5
Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.游离前列腺特异性抗原百分比在前列腺疾病诊断中的准确性及其在前列腺癌患者监测中的应用价值。
Urol Int. 2001;67(4):272-82. doi: 10.1159/000051003.
6
Is free prostate-specific antigen helpful in the differential diagnosis of benign hyperplasia and cancer of the prostate?
Tumour Biol. 1997;18(2):80-7. doi: 10.1159/000218017.
7
Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.游离前列腺特异性抗原百分比的测定有助于避免对直肠检查正常且总前列腺特异性抗原为4 - 10 ng/ml的男性进行不必要的活检。
Eur Urol. 2000 Mar;37(3):289-96. doi: 10.1159/000052358.
8
Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.复合前列腺特异性抗原（PSA）及计算游离PSA百分比在前列腺癌早期检测中的当代应用：疾病人口统计学变化的影响
Urology. 2001 Jun;57(6):1105-11. doi: 10.1016/s0090-4295(01)00953-0.
9
An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases.一种结合年龄、总前列腺特异性抗原（PSA）和游离PSA百分比来预测前列腺癌的算法：4298例病例的结果
Urology. 1998 Sep;52(3):455-61. doi: 10.1016/s0090-4295(98)00205-2.
10
[Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].[前列腺特异性抗原在前列腺增生中的鉴别诊断价值]
Urologiia. 2001 Mar-Apr(2):37-40.

引用本文的文献

1
Age-specific percentile-based prostate-specific antigen cutoff values predict the risk of prostate cancer: A single hospital observation.基于年龄百分位数的前列腺特异性抗原临界值可预测前列腺癌风险：一项单中心医院观察研究。
Biomedicine (Taipei). 2023 Sep 1;13(3):9-24. doi: 10.37796/2211-8039.1415. eCollection 2023.
2
Clinical efficacy of prostate PI-RADS V2.1 score combined with serum PSA-related indicators in the detection of gray zone prostate cancer.前列腺 PI-RADS V2.1 评分联合血清 PSA 相关指标在灰区前列腺癌检测中的临床效能。
Int Urol Nephrol. 2023 Nov;55(11):2685-2693. doi: 10.1007/s11255-023-03692-0. Epub 2023 Jul 31.
3
Knockdown of ferritin heavy chain (FTH) inhibits the migration of prostate cancer through reducing S100A4, S100A2, and S100P expression.
铁蛋白重链（FTH）的敲低通过降低S100A4、S100A2和S100P的表达来抑制前列腺癌的迁移。
Transl Cancer Res. 2020 Sep;9(9):5418-5429. doi: 10.21037/tcr-19-2852.
4
Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?用复合 PSA 和复合/总 PSA 比值检测前列腺癌——有优势吗？
Eur J Med Res. 2011 Oct 10;16(10):445-50. doi: 10.1186/2047-783x-16-10-445.